Volver

Boston Scientific Corp

Ticker: BSX ISIN: US1011371077
Añadir al portafolio Análisis de cartera en 2min
Stock Large-cap
Capitalización
83,24 MM $
P/E
23,43
Forward P/E
16,61
Profit margin
17,29%
Revenue growth QoQ
11,60%
Beta
0,62
49,01 $ -2,70%
Precio a fecha de 2026-08-24 · NYSE

Rendimiento por período

Rendimientos acumulados
1 Month +7,69%
6 Months -34,78%
1 Year -53,37%
5 Years +1,88% p.a.+9,74%
10 Years +7,27% p.a.+101,69%
Since inception +6,77% p.a.+413,19%
Rendimientos por año
YTD -48,60%
2025 +6,75%
2024 +54,51%
2023 +24,94%
2022 +8,92%
2021 +18,16%

Key stats

Market cap
83,24 MM
P/E
23,43
Beta
0,62
52-week range
54.98 - 109.50
50-day MA
65,84
200-day MA
89,28
Section 1

Business overview

Company profile data from fundamentals.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Sector Healthcare
Industry Medical Devices
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 14,66%
ROA 6,07%
Profit margin 17,29%
Operating margin 20,60%
PEG ratio 0,68
Revenue/share TTM 13,91
Revenue TTM 20,61 MM
EBITDA 5,50 MM
Gross profit TTM 14,21 MM
Beta 0,62

Valuation

Trailing P/E 23,43
Forward P/E 16,61
P/B 3,22
P/S 4,04
EV/EBITDA 16,89
EV/Revenue 4,50

ESG Scores

Total ESG 29,2
Environment 1,5
Social 12,9
Governance 7,9
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 3,38
Quarterly earnings growth 100,00%
Revenue TTM 20,61 MM
Reported quarters 119
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0,00%
Split factor 2:1
Last split date 2003-11-06
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 117,02 $
Analyst rating 4.5882

Ownership & short interest

Shares outstanding 1,48 MM
Shares float 1,48 MM
Institutional ownership 93,65%
Insider ownership 18,80%
Short ratio 1,66
Short % of float 1,73%

Details

Instrument metadata and source update timestamps.

Symbol BSX
Name Boston Scientific Corp
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US1011371077
Country USA
Code + exchange BSX.NYSE
Fundamentals updated 2026-05-07

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.